Inovio Pharmaceuticals (INO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

INO Stock Forecast

Inovio Pharmaceuticals stock forecast is as follows: an average price target of $8.00 (represents a 334.78% upside from INO’s last price of $1.84) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

INO Price Target

The average price target for Inovio Pharmaceuticals (INO) is $8.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 334.78% upside from INO's last price of $1.84.

INO Analyst Ratings

Buy

According to 4 Wall Street analysts, Inovio Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for INO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Inovio Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 09, 2024	Gregory Renza	RBC Capital	$8.00	$8.71	-8.15%	334.78%
May 14, 2024	Hartaj Singh	Oppenheimer	$40.00	$11.45	249.50%	2073.91%
May 13, 2024	Sudan Loganathan	Stephens	$20.00	$11.36	76.06%	986.96%
Jan 25, 2024	Hartaj Singh	Oppenheimer	$4.00	$6.79	-41.09%	117.39%

The latest Inovio Pharmaceuticals stock forecast, released on Aug 09, 2024 by Gregory Renza from RBC Capital, set a price target of $8.00, which represents a -8.15% decrease from the stock price at the time of the forecast ($8.71), and a 334.78% increase from INO last price ($1.84).

Inovio Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$18.00
Last Closing Price	$1.84	$1.84	$1.84
Upside/Downside	-100.00%	-100.00%	878.26%

In the current month, the average price target of Inovio Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Inovio Pharmaceuticals's last price of $1.84. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 18, 2024	Oppenheimer	Outperform	Outperform	Hold
Oct 04, 2024	Oppenheimer	Underperform	Underperform	Hold
Oct 04, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Aug 09, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
May 14, 2024	Oppenheimer	Outperform	Outperform	Hold
May 14, 2024	H.C. Wainwright	Neutral	Neutral	Hold
May 13, 2024	Stephens		Overweight	Initialise
Jan 25, 2024	Oppenheimer		Outperform	Upgrade

Inovio Pharmaceuticals's last stock rating was published by Oppenheimer on Nov 18, 2024. The company gave INO a "Outperform" rating, the same as its previous rate.

Inovio Pharmaceuticals Financial Forecast

Inovio Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$388.45M	-	$114.94K	$124.67K	$9.15M	$784.39K	$199.07K	$839.12K	$291.70K	$272.82K	$371.12K	$5.58M	$236.18K	$267.19K	$1.33M	$279.49K	$866.86K	$135.67K	$2.83M	$1.53M	$10.38M
Avg Forecast	$100.00K	$100.00K	$100.00K	$100.00K	$54.17K	$112.83K	$134.00K	$158.33K	$360.00K	$116.67K	$275.00K	$275.00K	$339.28K	$623.17K	$529.00K	$773.00K	$2.52M	$873.60K	$1.09M	$1.06M	$1.22M	$3.05M	$2.61M	$1.91M	$2.17M	$3.93M	$4.02M	$6.41M	$467.50K	$10.38M
High Forecast	$100.00K	$100.00K	$100.00K	$100.00K	$54.17K	$112.92K	$134.00K	$162.50K	$373.85K	$116.83K	$275.00K	$275.00K	$339.28K	$623.17K	$529.00K	$773.00K	$2.52M	$873.60K	$1.09M	$1.06M	$1.22M	$3.05M	$2.61M	$1.91M	$2.17M	$3.93M	$4.02M	$6.41M	$561.00K	$12.46M
Low Forecast	$100.00K	$100.00K	$100.00K	$100.00K	$54.17K	$112.75K	$134.00K	$154.17K	$346.15K	$116.50K	$275.00K	$275.00K	$339.28K	$623.17K	$529.00K	$773.00K	$2.52M	$873.60K	$1.09M	$1.06M	$1.22M	$3.05M	$2.61M	$1.91M	$2.17M	$3.93M	$4.02M	$6.41M	$374.00K	$8.30M
# Analysts	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	5	5	9	6	4	4	7	4	11	7
Surprise %	-	-	-	-	-	-	-	-	-	3329.53%	-	0.42%	0.37%	14.69%	1.48%	0.26%	0.33%	0.33%	0.25%	0.35%	4.57%	0.08%	0.10%	0.69%	0.13%	0.22%	0.03%	0.44%	3.27%	1.00%

Inovio Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $360.00K, with a low forecast of $346.15K, and a high forecast of $373.85K. INO's average Quarter revenue forecast represents a -99.91% decrease compared to the company's last Quarter revenue of $388.45M (Sep 23).

Inovio Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	5	5	9	6	4	4	7	4	11	7
EBITDA	-	-	-	-	-	-	-	-	-	$-35.55B	-	$-43.55M	$-56.94M	$-34.28M	$-102.81M	$-70.38M	$-102.17M	$-58.38M	$-80.98M	$-51.81M	$-26.20M	$-7.77M	$-31.36M	$-10.84M	$-29.28M	$-23.66M	$-23.44M	$-27.34M	$-31.32M	$-21.12M
Avg Forecast	$-100.00K	$-100.00K	$-100.00K	$-100.00K	$-54.17K	$-112.83K	$-134.00K	$-158.33K	$-360.00K	$-116.67K	$-275.00K	$-275.00K	$-339.28K	$-623.17K	$-529.00K	$-72.83M	$-2.52M	$-873.60K	$-1.09M	$-29.20M	$-1.22M	$-3.05M	$-2.61M	$-23.33M	$-2.17M	$-3.93M	$-4.02M	$-23.76M	$-36.76M	$-22.16M
High Forecast	$-100.00K	$-100.00K	$-100.00K	$-100.00K	$-54.17K	$-112.75K	$-134.00K	$-154.17K	$-346.15K	$-116.50K	$-275.00K	$-275.00K	$-339.28K	$-623.17K	$-529.00K	$-58.27M	$-2.52M	$-873.60K	$-1.09M	$-23.36M	$-1.22M	$-3.05M	$-2.61M	$-18.67M	$-2.17M	$-3.93M	$-4.02M	$-19.01M	$-29.40M	$-17.73M
Low Forecast	$-100.00K	$-100.00K	$-100.00K	$-100.00K	$-54.17K	$-112.92K	$-134.00K	$-162.50K	$-373.85K	$-116.83K	$-275.00K	$-275.00K	$-339.28K	$-623.17K	$-529.00K	$-87.40M	$-2.52M	$-873.60K	$-1.09M	$-35.04M	$-1.22M	$-3.05M	$-2.61M	$-28.00M	$-2.17M	$-3.93M	$-4.02M	$-28.52M	$-44.11M	$-26.59M
Surprise %	-	-	-	-	-	-	-	-	-	304739.23%	-	158.38%	167.84%	55.00%	194.34%	0.97%	40.52%	66.82%	74.24%	1.77%	21.47%	2.55%	12.03%	0.46%	13.46%	6.02%	5.82%	1.15%	0.85%	0.95%

undefined analysts predict INO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Inovio Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Inovio Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	5	5	9	6	4	4	7	4	11	7
Net Income	-	-	-	-	-	-	-	-	-	$-33.93B	-	$2.95B	$-51.67M	$-39.62M	$-112.46M	$-83.91M	$-109.00M	$-60.62M	$-82.00M	$-55.25M	$-17.59M	$19.17M	$-128.70M	$-32.54M	$-38.15M	$-22.24M	$-29.58M	$-29.29M	$-32.35M	$-24.12M
Avg Forecast	$-19.14M	$-21.95M	$-25.33M	$-30.39M	$-25.80M	$-32.36M	$-31.00M	$-28.52M	$-33.37M	$-42.77M	$-48.96M	$-48.96M	$-56.73M	$-95.11M	$-101.18M	$-74.42M	$-102.99M	$-105.42M	$-81.27M	$-29.92M	$-69.76M	$-60.38M	$-53.85M	$-26.62M	$-76.93M	$-82.51M	$-92.23M	$-24.72M	$-41.17M	$-23.09M
High Forecast	$-19.14M	$-21.95M	$-25.33M	$-30.39M	$-22.64M	$-32.36M	$-31.00M	$-28.52M	$-27.88M	$-42.77M	$-48.96M	$-48.96M	$-56.73M	$-95.11M	$-101.18M	$-59.54M	$-102.99M	$-105.42M	$-81.27M	$-23.94M	$-69.76M	$-60.38M	$-53.85M	$-21.30M	$-76.93M	$-82.51M	$-92.23M	$-19.78M	$-32.94M	$-18.47M
Low Forecast	$-19.14M	$-21.95M	$-25.33M	$-30.39M	$-27.37M	$-32.36M	$-31.00M	$-28.52M	$-38.66M	$-42.77M	$-48.96M	$-48.96M	$-56.73M	$-95.11M	$-101.18M	$-89.31M	$-102.99M	$-105.42M	$-81.27M	$-35.91M	$-69.76M	$-60.38M	$-53.85M	$-31.95M	$-76.93M	$-82.51M	$-92.23M	$-29.67M	$-49.41M	$-27.70M
Surprise %	-	-	-	-	-	-	-	-	-	793.24%	-	-60.22%	0.91%	0.42%	1.11%	1.13%	1.06%	0.58%	1.01%	1.85%	0.25%	-0.32%	2.39%	1.22%	0.50%	0.27%	0.32%	1.18%	0.79%	1.04%

Inovio Pharmaceuticals's average Quarter net income forecast for Jun 23 is $-48.96M, with a range of $-48.96M to $-48.96M. INO's average Quarter net income forecast represents a -101.66% decrease compared to the company's last Quarter net income of $2.95B (Mar 23).

Inovio Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	5	5	9	6	4	4	7	4	11	7
SG&A	-	-	-	-	-	-	-	-	-	$9.93B	-	$13.89M	$13.95M	$11.82M	$48.46M	$15.95M	$14.05M	$13.16M	$12.67M	$13.88M	$8.62M	$10.11M	$11.07M	$7.45M	$8.70M	$5.68M	$5.85M	$6.98M	$9.70M	$7.77M
Avg Forecast	$2.16M	$2.16M	$2.16M	$2.16M	$1.17M	$2.44M	$2.89M	$3.42M	$7.77M	$2.52M	$5.93M	$5.93M	$7.32M	$12.92M	$10.97M	$16.03M	$52.30M	$18.12M	$22.62M	$22.00M	$25.30M	$63.17M	$54.08M	$39.66M	$45.11M	$81.46M	$83.47M	$5.90M	$9.70M	$7.77M
High Forecast	$2.16M	$2.16M	$2.16M	$2.16M	$1.17M	$2.44M	$2.89M	$3.51M	$8.07M	$2.52M	$5.93M	$5.93M	$7.32M	$12.92M	$10.97M	$16.03M	$52.30M	$18.12M	$22.62M	$22.00M	$25.30M	$63.17M	$54.08M	$39.66M	$45.11M	$81.46M	$83.47M	$7.08M	$11.63M	$9.32M
Low Forecast	$2.16M	$2.16M	$2.16M	$2.16M	$1.17M	$2.43M	$2.89M	$3.33M	$7.47M	$2.51M	$5.93M	$5.93M	$7.32M	$12.92M	$10.97M	$16.03M	$52.30M	$18.12M	$22.62M	$22.00M	$25.30M	$63.17M	$54.08M	$39.66M	$45.11M	$81.46M	$83.47M	$4.72M	$7.76M	$6.21M
Surprise %	-	-	-	-	-	-	-	-	-	3941.93%	-	2.34%	1.91%	0.91%	4.42%	1.00%	0.27%	0.73%	0.56%	0.63%	0.34%	0.16%	0.20%	0.19%	0.19%	0.07%	0.07%	1.18%	1.00%	1.00%

Inovio Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $7.77M, based on 3 Wall Street analysts, with a range of $7.47M to $8.07M. The forecast indicates a -99.92% fall compared to INO last annual SG&A of $9.93B (Sep 23).

Inovio Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	5	5	9	6	4	4	7	4	11	7
EPS	-	-	-	-	-	-	-	-	-	$-0.13	-	$11.41	$-0.22	$-0.16	$-0.48	$-0.38	$-0.52	$-0.29	$-0.39	$-0.27	$-0.11	$0.31	$-1.43	$-0.41	$-0.31	$-0.22	$-0.30	$-0.30	$-0.36	$-0.33
Avg Forecast	$-0.68	$-0.78	$-0.90	$-1.08	$-0.92	$-1.15	$-1.10	$-1.01	$-1.19	$-1.52	$-1.74	$-1.74	$-2.02	$-3.50	$-3.72	$-4.13	$-3.79	$-3.88	$-2.99	$-2.23	$-2.56	$-2.22	$-1.98	$-2.66	$-2.83	$-3.03	$-3.39	$-3.08	$-0.14	$-0.31
High Forecast	$-0.68	$-0.78	$-0.90	$-1.08	$-0.80	$-1.15	$-1.10	$-1.01	$-0.99	$-1.52	$-1.74	$-1.74	$-2.02	$-3.50	$-3.72	$-4.13	$-3.79	$-3.88	$-2.99	$-2.23	$-2.56	$-2.22	$-1.98	$-2.66	$-2.83	$-3.03	$-3.39	$-3.08	$-0.11	$-0.25
Low Forecast	$-0.68	$-0.78	$-0.90	$-1.08	$-0.97	$-1.15	$-1.10	$-1.01	$-1.37	$-1.52	$-1.74	$-1.74	$-2.02	$-3.50	$-3.72	$-4.13	$-3.79	$-3.88	$-2.99	$-2.23	$-2.56	$-2.22	$-1.98	$-2.66	$-2.83	$-3.03	$-3.39	$-3.08	$-0.17	$-0.37
Surprise %	-	-	-	-	-	-	-	-	-	0.09%	-	-6.56%	0.11%	0.05%	0.13%	0.09%	0.14%	0.07%	0.13%	0.12%	0.04%	-0.14%	0.72%	0.15%	0.11%	0.07%	0.09%	0.10%	2.57%	1.06%

According to 1 Wall Street analysts, Inovio Pharmaceuticals's projected average Quarter EPS for Jun 23 is $-1.74, with a low estimate of $-1.74 and a high estimate of $-1.74. This represents a -115.25% decrease compared to INO previous annual EPS of $11.41 (Mar 23).

Inovio Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
INO	Inovio Pharmaceuticals	$1.96	$8.00	308.16%	Buy
VXRT	Vaxart	$0.59	$2.00	238.98%	Hold
NVAX	Novavax	$9.00	$20.33	125.89%	Buy

INO Forecast FAQ

Is Inovio Pharmaceuticals a good buy?

Yes, according to 4 Wall Street analysts, Inovio Pharmaceuticals (INO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of INO's total ratings.

What is INO's price target?

Inovio Pharmaceuticals (INO) average price target is $8 with a range of $8 to $8, implying a 334.78% from its last price of $1.84. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Inovio Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for INO stock, the company can go up by 334.78% (from the last price of $1.84 to the average price target of $8), up by 334.78% based on the highest stock price target, and up by 334.78% based on the lowest stock price target.

Can Inovio Pharmaceuticals stock reach $3?

INO's average twelve months analyst stock price target of $8 supports the claim that Inovio Pharmaceuticals can reach $3 in the near future.

What are Inovio Pharmaceuticals's analysts' financial forecasts?

Inovio Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $459.33K (high $463.58K, low $455.08K), average EBITDA is $-459K (high $-455K, low $-464K), average net income is $-118M (high $-115M, low $-119M), average SG&A $9.91M (high $10M, low $9.82M), and average EPS is $-4.182 (high $-4.069, low $-4.238). INO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $400K (high $400K, low $400K), average EBITDA is $-400K (high $-400K, low $-400K), average net income is $-96.803M (high $-96.803M, low $-96.803M), average SG&A $8.63M (high $8.63M, low $8.63M), and average EPS is $-3.44 (high $-3.44, low $-3.44).

Did the INO's actual financial results beat the analysts' financial forecasts?

Based on Inovio Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $832.01M, beating the average analysts forecast of $1.03M by 80939.91%. Apple's EBITDA was $-144B, beating the average prediction of $-1.027M by 14020028.05%. The company's net income was $-135B, beating the average estimation of $-174M by 77519.25%. Apple's SG&A was $47.58B, beating the average forecast of $22.16M by 214652.50%. Lastly, the company's EPS was $-6.09, missing the average prediction of $-6.186 by -1.55%. In terms of the last quarterly report (Sep 2023), Inovio Pharmaceuticals's revenue was $388.45M, beating the average analysts' forecast of $116.67K by 332852.76%. The company's EBITDA was $-35.553B, beating the average prediction of $-117K by 30473823.22%. Inovio Pharmaceuticals's net income was $-33.93B, beating the average estimation of $-42.774M by 79224.39%. The company's SG&A was $9.93B, beating the average forecast of $2.52M by 394093.18%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-1.52 by -91.45%